Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers
12.5.2022 09:00:00 EEST | Business Wire | Press release
Crown Bioscience and Medical & Biological Laboratories (MBL), JSR Life Sciences companies, today announced the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511005724/en/
Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanese Customers (Photo: Business Wire)
The new entity named “Crown Bioscience & MBL”, is a long-term strategic partnership that is expected to accelerate growth for both companies. The initial focus is to provide preclinical and translational services to expand Crown Bioscience’s offerings in Japan. The agreement will enhance Crown Bioscience’s current distributor model and establish a local presence to ensure premium service delivery in Japan.
Based in Tokyo, Crown Bioscience & MBL will establish a local team led by an experienced General Manager, Hiroki Itou, Executive Officer of MBL and General Manager, Diagnostic & Research Reagents Department at JSR.
The new company will leverage each organisations’ respective areas of excellence and expertise, combining Crown Bioscience’s world-class preclinical and translational service capabilities with MBL’s deep knowledge and experience of the Japanese pharmaceutical market. The company, established in April 2022, is expected to initiate services from September 2022.
Commenting on the establishment of the new company, Armin Spura PhD, CEO of Crown Bioscience, noted that the agreement will extend and deepen the current partnership with MBL. He said: “Japan will play a significant part in Crown Bioscience and MBL’s long-term strategic vision. Our new company has been created to better serve the evolving needs of the Japanese biopharmaceutical community, and to serve our Japanese customers more effectively. I am excited to further develop our synergies with MBL – a trusted partner in the Japanese life sciences sector.”
Hiroki Itou, President of Crown Bioscience & MBL commented: “Our two companies share a deep respect and identical values in the way we conduct business. I am confident that together we will be able to provide a unique and innovative portfolio of services that will accelerate drug discovery and development in Japan.”
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases (IMID). The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has ten facilities in the US, Europe and Asia. Find out more: www.crownbio.com.
About Medical & Biological Laboratories Co., Ltd.
Medical & Biological Laboratories (MBL) was established in 1969 as the first antibody manufacturer in Japan, and researches, develops, manufactures, and sells reagents of in vitro diagnostics (IVD) and reagents for basic research. It has now expanded its business not only to the immunological field but also to the field of genetic diagnosis. In the IVD business, we develop and sell IVD reagents for autoimmune diseases, cancer, infectious diseases, etc. Particularly in the field of autoantibody diagnosis, we are expanding our product lineup as a top manufacturer in Japan and contributing to medical care in this field where there are many intractable diseases. In the field of oncology, we are contributing to personalized medicine by developing companion diagnostics that predict the effects of drugs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005724/en/
Contact information
Media Enquiries:
Crown Bioscience
Louise Stenson
pr@crownbio.com
Medical & Biological Laboratories
Youichi Kozuka
kouhou@mbl.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sitetracker Selected by BNZ to Support Scalable Multitechnology Renewable Energy Growth Across Southern Europe30.9.2026 13:07:00 EEST | Press release
Sitetracker, the global leader in complete Asset Lifecycle Management for critical infrastructure, today announced that BNZ, an independent power producer (IPP) focused on renewable energy across Southern Europe, has selected Sitetracker to streamline and scale the management of its growing multitechnology portfolio. BNZ develops, builds, and operates utility-scale renewable energy assets across Spain, Italy, and Portugal. Its portfolio exceeds 2.7 GW across development, construction, and operation, including 530 MW connected and 222 MW under construction. To support its continued growth, BNZ sought a centralized platform to improve visibility, standardize workflows, and strengthen operational efficiency across the full asset lifecycle. “The next generation of renewable energy leaders will be defined by how efficiently they can scale,” said Giuseppe Incitti, CEO of Sitetracker. “BNZ is taking a proactive approach to building the operational infrastructure needed to support long-term gr
Linesight Appoints John Butler as CEO30.9.2026 13:00:00 EEST | Press release
Linesight, the global construction consultancy, today announced the appointment of John Butler as Chief Executive Officer, effective 1 January 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930482486/en/ John Butler, incoming CEO of Linesight (left), and Paul Boylan, Group CEO of IPS-Integrated Project Services, LLC (right). Butler will become CEO of Linesight effective 1 January 2027, succeeding Boylan, who will continue to lead the wider group. Butler will succeed Paul Boylan, who will remain closely involved with Linesight and its clients as Group CEO of IPS-Integrated Project Services, LLC (IPS). Boylan will continue to lead this wider group, encompassing IPS, Linesight and Springtide. Today, the group comprises of more than 4,500 people and generates approximately $2 billion in net revenue, providing multi-sector solutions through its specialist brands. Linesight is a global construction consultancy with over 5
Carrier and PHINIA Recognized with ISG Paragon Awards North America 2026 for Transformation Delivered with LTM30.9.2026 11:30:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced that its clients PHINIA and Carrier have been recognized at the ISG Paragon Awards North America 2026. LTM received recognition in the Excellence category for its work with PHINIA and in the Transformation category for its work with Carrier. The ISG Paragon Awards recognize enterprise-provider partnerships that leverage technology, innovation, and new operating models to deliver measurable business impact. The recognitions highlight LTM's ability to help global enterprises accelerate transformation through industry expertise, technology innovation, and execution excellence. Carrier: Following significant M&A activities, Carrier, a global leader in intelligent climate and energy solutions, sought to address a fragmented technology landscape, siloed operating functions, and limited visibility into application ownership and costs across its 2,000+ application estate. LTM partnered closely with Carrier
RGI Expands Its Digital Insurance Proposition With the Acquisition of D4Next30.9.2026 11:00:00 EEST | Press release
RGI, the leading provider of digital solutions for the European insurance industry, announces the acquisition of D4Next, an insurance technology company specializing in solutions that connect insurance products, distribution channels and digital processes, powered by innovative AI models. The acquisition broadens RGI’s ability to support insurers in addressing one of the key challenges facing the industry: how to accelerate business and technological innovation while progressively evolving an increasingly complex technology landscape. Supporting the evolution of insurance at the pace of the market As insurers continue to invest in new products, digital channels, distribution models and more intelligent processes, the ability to introduce innovation progressively, and connect new capabilities with the technologies already supporting the business, is becoming increasingly important. With the acquisition of D4Next, RGI expands its proposition with capabilities designed to support this evo
Roquette to Showcase End-to-End Pharma Solutions for Patient-Centric Formulations at CPHI Milan 202630.9.2026 11:00:00 EEST | Press release
Roquette will showcase its end-to-end portfolio of pharmaceutical excipients, drug delivery solutions and leading technical expertise at CPHI Milan 2026 in Italy, where the company will welcome visitors at booth 1A18 in the excipients hall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929017969/en/ Visit Roquette at booth 1A18 in the excipients hall. At this year’s global industry event, Roquette will highlight key product brands supporting formulation performance, patient-centric drug delivery and biopharma innovation, including METHOCEL™ cellulose ethers, PEARLITOL® mannitol, Avicel® microcrystalline cellulose, POLYOX™ polyethylene oxide, KLEPTOSE® cyclodextrins, LYCADEX® pyrogen-free dextrose monohydrate, Qualicaps™ by Roquette hard capsules and its alginate portfolio from sustainably sourced seaweed. The company will also spotlight its biopharma solutions spanning upstream processing, downstream efficiency, and form
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom